Generic Name and Formulations:
Epinephrine 0.1mg, 0.15mg, 0.3mg; pre-filled auto-injector (includes audible and visible cues for use).
Indications for AUVI-Q:
Emergency treatment of allergic reactions (Type 1) including anaphylaxis.
Adults and Children:
<7.5kg: not established. Inject IM or SQ only into the anterolateral aspect of the thigh. 7.5–15kg: 0.1mg. 15–30kg: 0.15mg. ≥30kg: 0.3mg. May repeat another dose if needed.
The presence of sulfite in this product should not deter use. Cardiovascular disease. Hypertension. Hyperthyroidism. Diabetes. Parkinson's disease. Injection-related complications: do not inject intravenously or into buttock (risk of Clostridial infections), digits, hands, or feet; hold leg firmly and limit movement in children prior to and during injection. Advise patient to seek medical help immediately. Train patient in use of device. Elderly. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by MAOIs, tricyclic antidepressants, levothyroxine, antihistamines (eg, chlorpheniramine, tripelennamine, diphenhydramine). May be antagonized by β-blockers (eg, propranolol), α-blockers (eg, phentolamine), ergot alkaloids. Arrhythmias possible with cardiac glycosides, diuretics, or anti-arrhythmics.
Anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea, vomiting, headache, respiratory difficulties; arrhythmias; rare: serious infections (skin and soft tissue) at injection site.
Cartons—2 (w. one Auvi-Q Trainer)
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Effects of a Low-Carbohydrate Diet on Weight Loss Maintenance
- Hypothyroidism Treatment No Longer Available
- Endocrine-Disrupting Chemicals in Personal Care Products Linked to Early Puberty
- Normalized HbA1c Levels Facilitate Improved Neuropathy Outcomes in T2D
- Parental Perception of Child Weight Status Predicted by Child BMI z Scores
- Fear Impacts Quality of Life for Young Adults With Type 1 Diabetes
- Five-Year Efficacy Data Announced for Liletta Intrauterine System
- AMA Code of Medical Ethics Guides Physicians in Fighting Harmful Online Health Information